Home › Companies › CORBUS PHARMACEUTICALS HOLDINGS INC. › 2023-2024
At CORBUS PHARMACEUTICALS HOLDINGS INC.'s shareholder meeting held May 16, 2024, in the 2023-2024 proxy season, 62 asset managers reported how they voted in their SEC Form N-PX filings, covering 332 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, On An Advisory Basis, Of The Executive Compensation Of The Company's Named Executive… — FOR was 99.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CORBUS PHARMACEUTICALS HOLDINGS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CORBUS PHARMACEUTICALS HOLDINGS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 16, 2024: 11 items on CORBUS PHARMACEUTICALS HOLDINGS INC.’s Form 8-K, filed May 20, 2024: 2 approved · 9 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore CORBUS PHARMACEUTICALS HOLDINGS INC. in the interactive database Compare manager voting policies
These tallies are CORBUS PHARMACEUTICALS HOLDINGS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Yuval Cohen | 6,629,030 | -- | -- | 19,144 | 1,962,726 | 99.7% | Not verified | — |
| Elect Director: Alan Holmer | 6,629,266 | -- | -- | 18,908 | 1,962,726 | 99.7% | Not verified | — |
| Elect Director: Avery W. Catlin | 6,192,121 | -- | -- | 456,053 | 1,962,726 | 93% | Not verified | — |
| Elect Director: Rachelle Jacques | 6,229,111 | -- | -- | 419,063 | 1,962,726 | 94% | Not verified | — |
| Elect Director: John Jenkins | 6,192,908 | -- | -- | 455,266 | 1,962,726 | 93% | Not verified | — |
| Elect Director: Peter Salzmann | 6,628,553 | -- | -- | 19,621 | 1,962,726 | 99.7% | Not verified | — |
| Elect Director: Anne Altmeyer | 6,191,380 | -- | -- | 456,794 | 1,962,726 | 93% | Not verified | — |
| Elect Director: Yong Ben | 6,629,521 | -- | -- | 18,653 | 1,962,726 | 99.7% | Not verified | — |
| 2. Proposal to approve the 2024 Plan | 3,961,184 | 2,681,336 | 5,654 | -- | 1,962,726 | 60% | Approved | — |
| 3. Proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 | 8,388,012 | 161,212 | 61,676 | -- | -- | 98% | Approved | — |
| The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement | 6,593,949 | 44,363 | 9,862 | -- | 1,962,726 | 99.3% | Not verified | — |
Source: CORBUS PHARMACEUTICALS HOLDINGS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.
Each item below shows how the 62 asset managers that disclosed a CORBUS PHARMACEUTICALS HOLDINGS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CORBUS PHARMACEUTICALS HOLDINGS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Alan Holmer
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Alan Holmer”): 6,629,266 for, 18,908 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 663,081 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Anne Altmeyer
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Anne Altmeyer”): 6,191,380 for, 456,794 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 229,991 for, 433,090 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 433,090 | Withhold |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Avery W. Catlin
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Avery W. Catlin”): 6,192,121 for, 456,053 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 229,991 for, 433,090 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 433,090 | Withhold |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: John Jenkins
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: John Jenkins”): 6,192,908 for, 455,266 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 229,991 for, 433,090 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 433,090 | Withhold |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Peter Salzmann
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Peter Salzmann”): 6,628,553 for, 19,621 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 663,081 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Rachelle Jacques
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Rachelle Jacques”): 6,229,111 for, 419,063 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 531,118 for, 128,563 withheld, 3,400 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 102,289 | Withhold |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 19,174 | Withhold |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 4,813 | Withhold |
| John Hancock | 70 | 0 | 3,400 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 1,858 | Withhold |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 429 | Withhold |
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Yong Ben
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Yong Ben”): 6,629,521 for, 18,653 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 663,081 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Yuval Cohen
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Elect Director: Yuval Cohen”): 6,629,030 for, 19,144 withheld, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 663,081 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
15% of fund votes cast · no official result
The 11 asset managers below reported 99,418 for, 560,281 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 433,090 | 0 | 0 | Against |
| T. Rowe Price | 0 | 102,289 | 0 | 0 | Against |
| Fidelity | 74,256 | 2,031 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 0 | 15,954 | 0 | 0 | Against |
| Aberdeen | 0 | 5,143 | 0 | 0 | Against |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| Equitable | 658 | 1,200 | 0 | 0 | Mixed |
| Nationwide | 0 | 574 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
| Belpointe Asset Management LLC | 88 | 0 | 0 | 0 | For |
Combines 8 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Approval, On An Advisory Basis, Of The Executive Compensation Of The Company's Named Executive Officers.
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“Proposal 4: The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statemen”): 6,593,949 for, 44,363 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 5,143 | 0 | 0 | Against |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Fund voting reports, all 11 managers: 657,938 for, 5,143 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,025,000 | 0 | 0 | 0 | For |
| Point72 | 701,597 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 624,652 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 405,000 | 0 | 0 | 0 | For |
| Citadel | 369,173 | 0 | 0 | 0 | For |
| Janus Henderson | 339,074 | 0 | 0 | 0 | For |
| BlackRock | 194,986 | 0 | 0 | 0 | For |
| T. Rowe Price | 123,689 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 88,934 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 84,773 | 0 | 0 | 0 | For |
| Altitude Crest Partners Inc. | 72,612 | 0 | 0 | 0 | For |
| Exome Asset Management LLC | 66,055 | 0 | 0 | 0 | For |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 64,503 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 63,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 47,827 | 0 | 0 | 0 | For |
| Prosight Management, LP | 45,297 | 0 | 0 | 0 | For |
| Woodline Partners LP | 39,899 | 0 | 0 | 0 | For |
| State Street | 35,979 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 27,184 | 0 | 0 | 0 | For |
| Northern Trust | 19,998 | 0 | 0 | 0 | For |
| Lighthouse Investment Partners, LLC | 12,045 | 0 | 0 | 0 | For |
| UBS | 7,500 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 5,143 | 0 | 0 | Against |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| Vanguard | 4,068 | 0 | 0 | 0 | For |
Institutional-manager reports, all 58 managers: 5,480,876 for, 5,399 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.
CORBUS PHARMACEUTICALS HOLDINGS INC.’s own tally for this item (“3. Proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024”): 8,388,012 for, 161,212 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was approved based upon the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 663,081 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 433,090 | 0 | 0 | 0 | For |
| T. Rowe Price | 102,289 | 0 | 0 | 0 | For |
| Fidelity | 76,287 | 0 | 0 | 0 | For |
| BlackRock | 19,174 | 0 | 0 | 0 | For |
| Dimensional | 15,954 | 0 | 0 | 0 | For |
| Aberdeen | 5,143 | 0 | 0 | 0 | For |
| Charles Schwab | 4,813 | 0 | 0 | 0 | For |
| John Hancock | 3,470 | 0 | 0 | 0 | For |
| Equitable | 1,858 | 0 | 0 | 0 | For |
| Nationwide | 574 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 429 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 10,686,693 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.05% |
| 2 | T. Rowe Price | 0.96% |
| 3 | Fidelity | 0.71% |
| 4 | BlackRock | 0.18% |
| 5 | Dimensional | 0.15% |
| 6 | Aberdeen | 0.05% |
| 7 | Charles Schwab | 0.05% |
| 8 | John Hancock | 0.03% |
| 9 | Equitable | 0.02% |
| 10 | Nationwide | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Cormorant Asset Management, LP | 18.95% |
| 2 | Point72 | 6.57% |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.85% |
| 4 | Octagon Capital Advisors LP | 3.79% |
| 5 | Citadel | 3.45% |
| 6 | Janus Henderson | 3.17% |
| 7 | BlackRock | 1.82% |
| 8 | T. Rowe Price | 1.16% |
| 9 | Eversept Partners, LP | 0.83% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.79% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Cormorant Global Healthcare Master Fund, LP | 18.95% | DEF14A |
| Adage Capital Partners, L.P. | 7.45% | DEF14A |
| OrbiMed Capital LLC | 6.72% | 13G |
| Point72 | 6.57% | 13F |
| Vanguard Group | 5.73% | 13F |
| Citadel Advisors | 3.62% | 13F |
| Millennium Management | 3.04% | 13F |
| Yuval Cohen | 2.16% | DEF14A |
| BlackRock | 2.12% | 13F |
| T. Rowe Price | 1.80% | 13F |
Percentages above are of 10,686,693 shares outstanding, as reported by CORBUS PHARMACEUTICALS HOLDINGS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CORBUS PHARMACEUTICALS HOLDINGS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CORBUS PHARMACEUTICALS HOLDINGS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “CORBUS PHARMACEUTICALS HOLDINGS (CRBP) 2024 Annual Meeting”, https://proxyvotesnow.com/company/corbus-pharmaceuticals-holdings-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.